Ranolazine Reduces Chest Pain Among Diabetics

Ranolazine effectively reduced chest pain and sublingual nitroglycerin use among diabetes patients with chronic angina, researchers reported in the Journal of the American College of Cardiology. In January, 2006, ranolazine (Ranexa) was approved by the U.S. Food and Drug Administration to treat chronic angina pectoris. The randomized, double-blind trial is the first of its kind to assess the effectiveness of ranolazine in reducing chest pain among people with diabetes...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Diabetes Source Type: news